Skip to content
    WuXi AppTec logo

    WuXi AppTec

    Shanghai, ChinaFounded 2000
    www.wuxiapptec.comLinkedIn
    Biotech & Life SciencesHealthcare

    WuXi AppTec is a global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization) headquartered in Shanghai that also operates a corporate venture arm, WuXi Healthcare Ventures, investing the parent company's capital in early-stage life sciences and healthcare startups across the U.S. and China. Its venture arm's second fund (WuXi Healthcare Ventures II, L.P.) closed at $290 million in December 2015, targeting cross-border Series A and B investments in therapeutics, diagnostics, and platform technologies.

    64% of their portfolio is in Biotech & Life Sciences. They made 1 investment in the last 12 months. Their most common stage is series-b (43% of deals). Average disclosed round size is $66.4M (across 24 rounds with reported amounts).

    Find people at WuXi AppTec on Goldilocks AI

    Portfolio

    24

    Fund Size

    $290M

    Top Stage

    Series B

    Last 12 Mo

    1

    Team

    Feng Zhang

    Feng Zhang

    Senior Vice President, API Manufacturing

    Florence Shi

    Florence Shi

    Senior Vice President, Chief Financial Officer

    Yu Lu

    Yu Lu

    Senior Vice President, WuXi TIDES, WuXi Chemistry Business Operations

    Zhaohui Zhang

    Zhaohui Zhang

    Executive Vice President, China Chief Operating Officer

    LL

    Lennart Lee

    Managing Director

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    28 investments
    CompanyRoundAmountDate
    D3 Bio logoD3 BioSeries C—Dec 2025
    CCutiaIpo$59MJan 2023
    Stemirna logoStemirnaSeries A$188MJun 2021
    LifeMine Therapeutics logoLifeMine TherapeuticsSeries B$50MJan 2021
    XW Pharma logoXW PharmaSeries C$40MSep 2020
    JW Therapeutics logoJW TherapeuticsSeries B$100MJun 2020
    XWPharma logoXWPharmaSeries C$40MJan 2020
    XXW LaboratoriesSeries C$58MJan 2020
    AArrakis TherapeuticsSeries B$75MApr 2019
    Arrakis logoArrakisSeries B$75MJan 2019
    Antengene logoAntengeneSeries B$120MJan 2019
    Fog Pharmaceuticals logoFog PharmaceuticalsSeries B$66MMay 2018
    CStone Pharmaceuticals logoCStone PharmaceuticalsSeries B$260MMay 2018
    RRefuge BiotechnologiesSeries B$25MMay 2018
    JW Therapeutics logoJW TherapeuticsSeries A$90MMar 2018
    IDEAYA Biosciences logoIDEAYA BiosciencesSeries B$94MMar 2018
    LifeMine Therapeutics logoLifeMine TherapeuticsSeries A$55MSep 2017
    Vivace Therapeutics logoVivace TherapeuticsSeries B$25MJun 2017
    Antengene logoAntengeneSeries A$21MJan 2017
    AnchorDx logoAnchorDxSeries B$28MJan 2017
    IDEAYA Biosciences logoIDEAYA BiosciencesSeries A$46MMay 2016
    MegaRobo logoMegaRoboSeries A—Jan 2016
    23andMe logo23andMeSeries E—Oct 2015
    Transcriptic logoTranscripticSeries A$8.5MFeb 2015
    Avelas Biosciences logoAvelas BiosciencesSeries B$6.8MJan 2014
    Page 1 of 2

    Top Co-Investors

    ARCH Venture Partners7 shared
    HongShan6 shared
    Alexandria Venture Investments6 shared
    GV6 shared
    WuXi Healthcare Ventures6 shared
    Celgene5 shared
    Canaan Partners5 shared
    Boyu Capital4 shared
    Fidelity Investments4 shared
    WI Harper Group4 shared
    Temasek Holdings (Private) Limited3 shared
    Blue Pool Capital3 shared
    Dimension3 shared
    Nextech Invest Ltd.3 shared
    Panacea Venture3 shared
    KTB Network3 shared
    MRL Ventures Fund2 shared
    Foresite Capital2 shared
    GG12 shared
    AMD Ventures2 shared

    Last updated: 20 October 2026